Arcus Biosciences Forecast, price target & analysts
Arcus Biosciences Target price 2025 - Analyst rating & recommendation
Arcus Biosciences Classifications & Recommendation:
Arcus Biosciences Price Target
| Target Price | $26.52 |
| Price | $7.95 |
| Potential |
233.59%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Arcus Biosciences 2026 .
The average Arcus Biosciences target price is $26.52.
This is
233.59%
register free of charge
$48.30
507.55%
register free of charge
$12.12
52.45%
register free of charge
|
|
| A rating was issued by 19 analysts: 16 Analysts recommend Arcus Biosciences to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcus Biosciences stock has an average upside potential 2026 of
233.59%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 258.00 | 119.42 |
| 120.51% | 53.71% | |
| EBITDA Margin | -116.28% | -397.45% |
| 59.02% | 241.81% | |
| Net Margin | -109.69% | -412.32% |
| 58.20% | 275.90% |
13 Analysts have issued a sales forecast Arcus Biosciences 2025 . The average Arcus Biosciences sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Arcus Biosciences EBITDA forecast 2025. The average Arcus Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Arcus Biosciences Analysts have issued a net profit forecast 2025. The average Arcus Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.14 | -4.65 |
| 24.34% | 48.09% | |
| P/E | negative | |
| EV/Sales | negative |
13 Analysts have issued a Arcus Biosciences forecast for earnings per share. The average Arcus Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Arcus Biosciences...
Current Arcus Biosciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Feb 19 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Apr 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 19 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 18 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
